304 related articles for article (PubMed ID: 32694169)
21. D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review.
Eljilany I; Elzouki AN
Vasc Health Risk Manag; 2020; 16():455-462. PubMed ID: 33223833
[TBL] [Abstract][Full Text] [Related]
22. Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implications.
Voicu S; Delrue M; Chousterman BG; Stépanian A; Bonnin P; Malissin I; Deye N; Neuwirth M; Ketfi C; Mebazaa A; Siguret V; Mégarbane B
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):9161-9168. PubMed ID: 32965009
[TBL] [Abstract][Full Text] [Related]
23. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients.
Roldán V; Marín F; Muiña B; Torregrosa JM; Hernández-Romero D; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2011 Jun; 57(25):2496-504. PubMed ID: 21497043
[TBL] [Abstract][Full Text] [Related]
24. Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.
Rieder M; Goller I; Jeserich M; Baldus N; Pollmeier L; Wirth L; Supady A; Bode C; Busch HJ; Schmid B; Duerschmied D; Gauchel N; Lother A
J Thromb Thrombolysis; 2020 Oct; 50(3):558-566. PubMed ID: 32617807
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis.
Yu B; Li X; Chen J; Ouyang M; Zhang H; Zhao X; Tang L; Luo Q; Xu M; Yang L; Huang G; Liu X; Tang J
J Thromb Thrombolysis; 2020 Oct; 50(3):548-557. PubMed ID: 32524516
[TBL] [Abstract][Full Text] [Related]
26. Increased ADAMTS13 activity in patients with venous thromboembolism.
Mazetto BM; Orsi FL; Barnabé A; De Paula EV; Flores-Nascimento MC; Annichino-Bizzacchi JM
Thromb Res; 2012 Dec; 130(6):889-93. PubMed ID: 23031329
[TBL] [Abstract][Full Text] [Related]
27. Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a case-control study.
De Cristofaro R; Liuzzo G; Sacco M; Lancellotti S; Pedicino D; Andreotti F
Blood Coagul Fibrinolysis; 2021 Jun; 32(4):285-289. PubMed ID: 33443926
[TBL] [Abstract][Full Text] [Related]
28. Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.
Karakaya B; Tombak A; Serin MS; Tiftik N
Hematology; 2016 Jun; 21(5):295-9. PubMed ID: 26872106
[TBL] [Abstract][Full Text] [Related]
29. Trends and diagnostic value of D-dimer levels in patients hospitalized with coronavirus disease 2019.
Creel-Bulos C; Liu M; Auld SC; Gaddh M; Kempton CL; Sharifpour M; Sniecinski RM; Maier CL; Nahab FB; Rangaraju S
Medicine (Baltimore); 2020 Nov; 99(46):e23186. PubMed ID: 33181697
[TBL] [Abstract][Full Text] [Related]
30. Unfavourably altered plasma clot properties in patients with primary Raynaud's phenomenon: association with venous thromboembolism.
Żuk J; Snarska-Drygalska A; Malinowski KP; Papuga-Szela E; Natorska J; Undas A
J Thromb Thrombolysis; 2019 Feb; 47(2):248-254. PubMed ID: 30684190
[TBL] [Abstract][Full Text] [Related]
31. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms.
Lip GY; Lowe GD; Metcalfe MJ; Rumley A; Dunn FG
Am J Cardiol; 1995 Sep; 76(7):453-8. PubMed ID: 7653443
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Venous Thromboembolism Risks Between COVID-19 Pneumonia and Community-Acquired Pneumonia Patients.
Mei F; Fan J; Yuan J; Liang Z; Wang K; Sun J; Guan W; Huang M; Li Y; Zhang WW
Arterioscler Thromb Vasc Biol; 2020 Sep; 40(9):2332-2337. PubMed ID: 32628040
[TBL] [Abstract][Full Text] [Related]
33. The ADAMTS13-von Willebrand factor axis in COVID-19 patients.
Mancini I; Baronciani L; Artoni A; Colpani P; Biganzoli M; Cozzi G; Novembrino C; Boscolo Anzoletti M; De Zan V; Pagliari MT; Gualtierotti R; Aliberti S; Panigada M; Grasselli G; Blasi F; Peyvandi F
J Thromb Haemost; 2021 Feb; 19(2):513-521. PubMed ID: 33230904
[TBL] [Abstract][Full Text] [Related]
34. Plasma levels of von Willebrand factor and plasminogen activator in patients with arterial thromboembolism--with special reference to their correlation to the increased catabolism of both fibrinogen and platelets.
Matsumoto M; Uchiyama T; Kobayashi N; Maekawa T
Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1105-14. PubMed ID: 2588960
[TBL] [Abstract][Full Text] [Related]
35. D-dimer and mortality in COVID-19: a self-fulfilling prophecy or a pathophysiological clue?
Breakey N; Escher R
Swiss Med Wkly; 2020 May; 150():w20293. PubMed ID: 32459857
[TBL] [Abstract][Full Text] [Related]
36. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels.
Demelo-Rodríguez P; Cervilla-Muñoz E; Ordieres-Ortega L; Parra-Virto A; Toledano-Macías M; Toledo-Samaniego N; García-García A; García-Fernández-Bravo I; Ji Z; de-Miguel-Diez J; Álvarez-Sala-Walther LA; Del-Toro-Cervera J; Galeano-Valle F
Thromb Res; 2020 Aug; 192():23-26. PubMed ID: 32405101
[TBL] [Abstract][Full Text] [Related]
37. Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients.
Joly BS; Darmon M; Dekimpe C; Dupont T; Dumas G; Yvin E; Beranger N; Vanhoorelbeke K; Azoulay E; Veyradier A
J Thromb Haemost; 2021 Sep; 19(9):2193-2198. PubMed ID: 34219357
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients.
Cheng A; Hu L; Wang Y; Huang L; Zhao L; Zhang C; Liu X; Xu R; Liu F; Li J; Ye D; Wang T; Lv Y; Liu Q
Int J Antimicrob Agents; 2020 Sep; 56(3):106110. PubMed ID: 32712332
[TBL] [Abstract][Full Text] [Related]
39. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19.
Rauch A; Labreuche J; Lassalle F; Goutay J; Caplan M; Charbonnier L; Rohn A; Jeanpierre E; Dupont A; Duhamel A; Faure K; Lambert M; Kipnis E; Garrigue D; Lenting PJ; Poissy J; Susen S
J Thromb Haemost; 2020 Nov; 18(11):2942-2953. PubMed ID: 32881304
[TBL] [Abstract][Full Text] [Related]
40. Research in brief: Coagulopathy in COVID-19: Determining and managing thrombotic risk in COVID-19 infection.
Pooni RS
Clin Med (Lond); 2020 Jul; 20(4):e59. PubMed ID: 32675158
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
